IPSEF News and Press, Ipsen Sa Ord From 04/17/20

Quick Take Lantern Pharma ( LTRN ) has filed to raise $28.75 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of drug candidates for the treatment of prostate, lung and other cancers. LTRN seeks to use its proprietary ...

Ipsen S.A. (IPSEY) Q4 2019 Earnings Conference Call February 13, 2020 8:30 AM ET Company Participants Aymeric Le Chatelier - Chief Executive Officer Conference Call Participants Michael Leuchten - UBS Ltd. Diana H W Na - Goldman Sachs Matthew Weston - Credit Suisse Delphi...

The following slide deck was published by Ipsen S.A. in conjunction with their 2019 Q4 earnings Read more ...

Editor's note: Seeking Alpha is proud to welcome Michal Kalisiak as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Company Ipsen...

Recently, Japan’s Ministry of Health, Labor and Welfare approved the company’s collaborating product MINNERBO with Daiichi Sankyo’s (OTCPK: OTCPK:DSKYF ) for the treatment of hypertension and Exelixis will receive $20 million. In addition, in December, Exelixis ( EXEL )...

The following slide deck was published by Ipsen S.A. in conjunction with this Read more ...

Exelixis (NASDAQ: EXEL ) and Ipsen ( OTCPK:IPSEF ) has initiated COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). More news on: Exelixis, Inc., Ip...

Exelixis (NASDAQ: EXEL ) announces that collaboration partner Ipsen ( OTCPK:IPSEF ) has received marketing approval from the European Commission for CABOMETYX (cabozantinib) as monotherapy in adult patients with hepatocellular carcinoma who have been previously treated with Bayer's Nexavar...

Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...

Ipsen Canada Appoints Ed Dybka as General Manager Canada NewsWire MISSISSAUGA, ON, Oct. 11, 2018 MISSISSAUGA, ON , Oct. 11, 2018 /CNW/ - Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dy...